Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel

Sponsor
Illumina, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT04561089
Collaborator
Helix OpCo, LLC (Other)
763
3
12.5
254.3
20.3

Study Details

Study Description

Brief Summary

"This is a prospective, multi-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis.

Positive results from COVIDSeq Test using saliva and/or the comparator EUA test will be provided to subjects so participants can be referred for further evaluation (outside the study). No medical treatment, guidance on treatment decisions, nor medical care will be provided. "

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: COVIDSeq Test

Study Design

Study Type:
Observational
Actual Enrollment :
763 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Evaluation of the COVIDSeq Test in Saliva Specimens From Illumina Personnel
Actual Study Start Date :
Feb 13, 2020
Actual Primary Completion Date :
Feb 28, 2021
Actual Study Completion Date :
Feb 28, 2021

Arms and Interventions

Arm Intervention/Treatment
COVID-19 asymptomatic population

COVID-19 asymptomatic Illumina personnel

Diagnostic Test: COVIDSeq Test
The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19

Outcome Measures

Primary Outcome Measures

  1. Positive percent agreement (PPA) and negative percent agreement (NPA) between the COVIDSeq Test and a comparator EUA test for the detection of SARS-CoV-2 RNA [1 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Subject Inclusion Criteria:

An individual must meet the criteria below to be eligible.

  • Individual is Illumina US personnel (eg, employee, contractor, consultant) and was invited to participate in the study.

  • Individual is 18 years or older at the time of consent.

  • Individual is feeling well and, at the time of consent or specimen collection, does not have any of the following symptoms of COVID-19: cough, shortness of breath or difficulty breathing, fatigue, fever or chills, muscle or body aches, headache, sore throat, new loss of taste or smell, congestion or runny nose, nausea or vomiting, or diarrhea. [1]

  • Individual is willing to participate in study procedures and able to provide written informed consent in the English language.

Subject Exclusion Criteria:

An individual cannot meet the below criteria.

  • Individual is confirmed to have COVID-19 and continues to require home isolation in accordance with current CDC guidelines at the time of consent or specimen collection.

  • Individual is asymptomatic but suspected to have COVID-19 due to recent close contact (as currently defined by the CDC) with a person with COVID-19 and continues to require quarantine in accordance with current CDC guidelines at the time of consent or specimen collection. [4]

  • Individual had symptoms of COVID-19 less than 10 days before time of consent or less than 10 days before time of any subsequent specimen collection visit."

Contacts and Locations

Locations

Site City State Country Postal Code
1 Illumina Laboratory Services Foster City California United States 94404
2 Illumina Hayward Hayward California United States 94545
3 Illumina Laboratory Services San Diego California United States 92122

Sponsors and Collaborators

  • Illumina, Inc.
  • Helix OpCo, LLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Illumina, Inc.
ClinicalTrials.gov Identifier:
NCT04561089
Other Study ID Numbers:
  • COVD-B07-001
First Posted:
Sep 23, 2020
Last Update Posted:
Jan 21, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jan 21, 2022